Hybrid Drug-Coated Balloon Strategy
The review found the hybrid DCB approach feasible and promising at about 12 months of clinical follow-up. The evidence base remains uncertain despite favorable findings. The strategy is intended to avoid leaving a permanent implant in the…
1 sources - 4 claims
The review found the hybrid DCB approach feasible and promising at about 12 months of clinical follow-up. The evidence base remains uncertain despite favorable findings. The strategy is intended to avoid leaving a permanent implant in the side branch. The hybrid DCB strategy uses a contemporary drug-eluting stent in the main vessel and a drug-coated balloon in the side branch.